Combination treatment of anti-PD-L1 plus anti-TGF-β was significantly more efficacious than anti-PD-L1 alone (p = 0.038) and led to tumor regression in four of six (66.67%) animals by day 28 (Fig. 1a, b). The gene discussed is TGFB1; the disease is neoplasm.